Ovid Therapeutics has initiated the pivotal Phase 3 NEPTUNE trial to evaluate the experimental small molecule OV101 for the treatment of Angelman syndrome. The trial expects to enroll approximately 60 children ages 4–12, with enrollment set to begin during the third quarter of 2019 and top-line data…
News
It wasn’t until Gordana Loleska’s son David was 14 years old that doctors in their native North Macedonia diagnosed his kidney, vision, and hearing problems as Alport syndrome. Although she had known for years that something was wrong, the news that David would battle a lifelong rare disease devastated…
A violinist with vasculitis, two Texas politicians and a pharmaceutical company whose marijuana-derived therapy helps kids with Dravet syndrome were among winners of the 2019 Rare Impact Awards. Officials of the National Organization for Rare Disorders (NORD) presented the awards during a June 22 dinner attended by…
Scientists, armed with new technologies, cracked a 20-year mystery surrounding a girl diagnosed with two rare inherited disorders, Angelman syndrome and cholesterol side-chain cleavage enzyme (P450scc) deficiency, by finding both have a common genetic origin. Their case report, “Adrenal Insufficiency, Sex Reversal, and Angelman Syndrome due to…
Europe’s umbrella organization for 800 rare disease associations has developed a sweeping initiative to help the continent’s 30 million rare disease patients and their caregivers learn about their conditions, find assistance and receive treatment. Eurordis-Rare Diseases Europe hopes to improve the current piecemeal treatment and support program with a holistic,…
People with rare diseases know that the right government policies can make a big difference in the quality of their own lives, and those of their caregivers. But most lawmakers aren’t experts in even one well-known disease — let alone the world’s estimated 7,000 rare disorders. So how does the…
Researchers have developed a new quick and accurate molecular diagnostic test for patients with either Angelman and Prader-Willi syndrome. Their study, “A rapid and accurate methylation‐sensitive high‐resolution melting analysis assay for the diagnosis of Prader Willi and Angelman patients,” was published in Molecular Genetics &…
RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site was developed by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of…
News
Roche Researcher Plans Clinical Trial Seeking Ways to Measure Disease Impact in Home and Clinic
Swiss pharmaceutical giant Roche plans to begin recruiting this summer for an endpoint study in Angelman syndrome that will not test any drug therapy. Instead, the study aims to find ways to measure disease impact in the home and clinic — and use new technologies to learn about…
Ovid Therapeutics’ experimental therapy OV101 has been shown to improve sleep, motor function, communication skills, and reduce challenging behavior and anxiety in patients with Angelman syndrome in a Phase 2 study. Results from the trial were recently discussed at the 2019 American Academy of Neurology’s (AAN)…
Recent Posts
- Goals that matter most for our child living with Angelman syndrome
- Home videos may help doctors evaluate Angelman patient skills
- After hesitation, we finally took steps to address our son’s disrupted sleep
- International Angelman Day: Why Feb. 15 matters for families
- Traveling with a child with Angelman syndrome is easier in the early years
- 6 months of keto diet shows promising trends for Angelman children
- Angelman syndrome has shaped how we celebrate our son’s birthday
- MVX-220 Angelman gene therapy trial enters first human testing
- Recognizing the importance of exercise for Angelman caregivers
- When the world forgets our children